Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Completes H Share Full Circulation Program
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Completion of H Share Full Circulation
Key Highlights
- Successful Completion of H Share Full Circulation: The company has completed the conversion of a total of 8,214,278 Domestic Shares and Unlisted Foreign Shares into H Shares, effective April 17, 2026.
- Commencement of Trading: The newly converted H Shares will begin trading on the Hong Kong Stock Exchange at 9:00 a.m. on April 20, 2026.
- Change in Share Capital Structure: Post-conversion, H Shares now represent 73.32% of the company’s total share capital, up from 69.80% prior to the conversion.
- Three Major Participants: The conversion involved three shareholders: Wealthy Linkage Limited, Future Industry Investment Fund Phase II (Limited Partnership), and Leyue Capital Limited.
Details of the H Share Full Circulation Program
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or “the Company”) has announced the completion of its H Share Full Circulation program. This significant milestone enables certain domestic and unlisted foreign shares to be converted into H Shares, thereby enhancing liquidity and offering greater accessibility for international and Hong Kong-based investors.
The Board confirmed that the conversion process, involving a total of 8,214,278 Domestic Shares and Unlisted Foreign Shares, was successfully completed on April 17, 2026. The listing and trading of these converted H Shares will officially commence at 9:00 a.m. on April 20, 2026.
Breakdown of Converted Shares and Shareholders Involved
| Participating Shareholder |
Number of Converted H Shares |
Percentage of Total Share Capital |
| Wealthy Linkage Limited |
3,633,914 |
1.56% |
| Future Industry Investment Fund Phase II (Limited Partnership) |
3,572,088 |
1.53% |
| Leyue Capital Limited |
1,008,276 |
0.43% |
| Total |
8,214,278 |
3.52% |
Updated Share Capital Structure
The completion of the conversion and listing of H Shares has resulted in a notable shift in the company’s share capital structure:
| Description of Shares |
Shares Before Conversion |
% of Total Capital |
Shares After Conversion |
% of Total Capital |
| Domestic Shares |
65,773,800 |
28.21% |
62,201,712 |
26.68% |
| Unlisted Foreign Shares |
4,642,190 |
1.99% |
0 |
0% |
| H Shares |
162,769,979 |
69.80% |
170,984,257 |
73.32% |
| Total |
233,185,969 |
100% |
233,185,969 |
100% |
Implications for Shareholders and Investors
- Increased Liquidity: The conversion of domestic and unlisted foreign shares into H Shares increases the liquidity of the Company’s shares, allowing for broader participation by international investors.
- Potential Impact on Share Price: The influx of new H Shares onto the market may influence the share price, depending on investor demand and market conditions.
- Ownership Diversification: The increased proportion of H Shares reduces the concentration of domestic shares, potentially leading to a more diverse and international shareholder base.
- Transparency and Regulatory Compliance: The process, conducted according to Hong Kong’s Listing Rules and relevant regulations, underscores the company’s commitment to transparency and good governance.
Board of Directors
The Board comprises Mr. LIU Gexin as chairman and non-executive Director, Dr. GE Junyou as executive Director, several other non-executive Directors, and four independent non-executive Directors. The Board remains committed to maximizing shareholder value and maintaining high governance standards.
Shareholder Caution
The Company has advised shareholders and potential investors to exercise caution when dealing in its securities, given the potential impact of the newly converted H Shares on market dynamics and share price.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own research or consult a licensed professional before making any investment decisions. The information is based on publicly available data as of April 17, 2026, and may be subject to change without notice.
View SKB BIO Historical chart here
